LOGIN  |  REGISTER
Chimerix

Regional Health Properties Announces Commencement of Trading of Series B Preferred Stock on OTC Markets

August 03, 2023 | Last Trade: US$1.51 0.01 -0.66

ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”) (NYSE American: RHE) (NYSE American: RHE-PA) (OTCQB Venture: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that its 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) commenced trading on the OTCQB Venture Market, operated by the OTC Markets Group, Inc., under the symbol “RHEPB”.

The Company’s Common Stock and Series A Redeemable Preferred Shares will continue to trade on the NYSE American LLC under the symbols “RHE” and “RHE-PA,” respectively. The Company will continue to file its required periodic reports and other filings with the Securities and Exchange Commission.

About Regional Health Properties

Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.

 
Company Contact
 

Brent Morrison, CFA
Chief Executive Officer & President
Regional Health Properties, Inc.
Tel (678) 368-4402
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Last Trade: US$1.51
Daily Change: -0.01 -0.66
Daily Volume: 13,842
Market Cap: US$2.870M

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB